Group Therapy With Transcranial Direct Current Stimulation in Patients With Parkinson's Disease (GTBQ-PD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04174573|
Recruitment Status : Not yet recruiting
First Posted : November 22, 2019
Last Update Posted : October 1, 2021
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Other: GTO Other: GT-tDCS||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||64 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Efficacy of Group Therapy With Transcranial Direct Current Stimulation on Balance and Quality of Life in Patients With Parkinson's Disease: A Single Blind, Multi-centre, Randomized Clinical Study|
|Estimated Study Start Date :||June 6, 2022|
|Estimated Primary Completion Date :||January 31, 2023|
|Estimated Study Completion Date :||October 1, 2023|
Experimental: Group therapy only (GTO)
Patients in GTO group will receive structured group therapy programme
Experimental: Group therapy with tDCS (GT-tDCS)
Patients in this group will receive group therapy along-with tDCS intervention
- Movement Disorders Society Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS). [ Time Frame: Change will be measured at baseline, 3 weeks and after 6 weeks of intervention ]The Unified Parkinson Disease Rating Scale, designed to monitor the burden and extent of Parkinson's disease. o-4 score, lower the score indicates normal, higher the scores indicate greater impact of PD symptoms.
- Parkinson's Disease Questionnaire with 39 items [ Time Frame: Change will be measured at baseline, 3 weeks and after 6 weeks of intervention ]
The PDQ-39 is a 39-item self-report questionnaire, which assesses Parkinson's disease-specific health related quality over the last month.
Assesses how often patients experience difficulties across the 8 quality of life dimensions.
Assesses impact of Parkinson's Disease (PD) on specific dimensions of functioning and well-being. Each dimension total score ranges from 0 (never have difficulty) to 100 (always have difficulty). lower score reflect better quality of life.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04174573
|Contact: Asir J Samuel, MPT, (Ph.D)||firstname.lastname@example.org|
|Contact: Adarsh K Srivastav, MPT||8618889003 ext email@example.com|
|Principal Investigator:||Adarsh K Srivastav, MPT||Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation|